MARKET

APLT

APLT

Applied
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.52
+0.71
+7.24%
After Hours: 10.52 0 0.00% 16:40 09/20 EDT
OPEN
10.25
PREV CLOSE
9.81
HIGH
10.84
LOW
9.60
VOLUME
143.68K
TURNOVER
--
52 WEEK HIGH
11.39
52 WEEK LOW
7.95
MARKET CAP
179.39M
P/E (TTM)
-20.5469
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of APLT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

APLT News

  • Applied Therapeutics To Present Preclinical Data Highlighting AT-001 For Treatment Of Diabetic Cardiomyopathy At EASD
  • Benzinga.3d ago
  • Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
  • GlobeNewswire.3d ago
  • Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
  • GlobeNewswire.09/13 12:00
  • Applied Therapeutics Reports Will Present Data Highlighting AT-001 For Treatment Of Diabetic Cardiomyopathy At HFSA Meeting
  • Benzinga.09/13 11:02

More

Industry

Biotechnology & Medical Research
+0.75%
Pharmaceuticals & Medical Research
+1.02%

Hot Stocks

Name
Price
%Change

About APLT

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.
More

Webull offers Applied Therapeutics Inc (APLT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.